What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial

BACKGROUND: Decisions about adjuvant therapy involve trade-offs between possible benefits and harms. OBJECTIVE: We sought to determine the survival benefits that clinical investigators would judge as sufficient to warrant treatment with adjuvant sorafenib in the SORCE trial after nephrectomy for app...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawrence, Nicola J., Martin, Andrew, Davis, Ian D., Troon, Simon, Sengupta, Shomik, Hovey, Elizabeth, Coskinas, Xanthi, Kaplan, Richard, Smith, Benjamin, Ritchie, Alastair, Meade, Angela, Eisen, Tim, Blinman, Prunella, Stockler, Martin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2018
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364092/
https://www.ncbi.nlm.nih.gov/pubmed/30740581
http://dx.doi.org/10.3233/KCA-180038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364092/
https://www.ncbi.nlm.nih.gov/pubmed/30740581
http://dx.doi.org/10.3233/KCA-180038

Ejemplares similares